VJHemOnc is committed to improving our service to you

MDS 2020 | Future MDS treatment options

VJHemOnc is committed to improving our service to you

Inga Mandac

Inga Mandac, MD, Clinical Hospital Merkur, Zagreb, Croatia, discusses future priorities to focus on combinational treatments with targeted agents or monoclonal antibodies for myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter